Five Prime: A Prime Play on Proteins

By: John McCamant

Following a recent meeting with top management at this firm, John McCamant—editor of The Medical Technology Stock Letter—has issued a buy recommendation for the early-stage biotech, noting that it could become a leader in immuno-oncology.

Steven Halpern: Our guest today is John McCamant, the newsletter industry’s leading biotechnology expert and editor of The Medical Technology Stock Letter. How are you doing today, John?

John McCamant: I’m doing great, Steve. How are you?

Steven Halpern: Very good. Thanks for joining us. Let’s begin with your overall outlook for the biotech sector and some of the industry catalysts that you think could impact the sector between now and yearend.

John McCamant: Okay. Well, basically, Steve, we’re looking at some of the technical indicators here early in the fall as we’ve recently crossed back over the 50-day and 200-day moving averages. Very important in biotechnology as far as we’ve had a volatile year-to-date and there’s a lot of people that watch or pay attention to the charts.